Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

541 Ioannidis J, Katsifis G, Tzioufas A, Moutsopoulos H. Predictors of sustained amenorrhea
from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus
erythematosus. J Rheumatol 2002; 29: 2129–2135.
542 Mok C, Lau C, Wong R. Risk factors for ovarian failure in patients with systemic lupus
erythematosus receiving cyclophosphamide therapy. Arthritis Rheumatol 1998; 41: 831–
837.
543 Park M, Park Y, Jung S, Chung I, Choi K, Lee S. Risk of ovarian failure and pregnancy
outcome in patients treated with intravenous cyclophosphamide pulse therapy. Lupus
2014; 13: 569–574.
544 Appenzeller S, Blatyta PF, Costallat LTL. Ovarian failure in SLE patients using pulse
cyclophosphamide: comparison of different regimes. Rheumatol Int 2008; 28: 567–571.
545 Martín-Gómez M, De Ramón-Garrido E, Frutos M. Pasado y presente del tratamiento
Inmunosupresor de la de la Nefritis Lúpica en la provincia de Málaga. 2011.
546 Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D et al.
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus
nephritis. J Am Soc Nephrol 2009; 20: 1103–1112.
547 Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O´Nan P et al. Sequential
therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–980.
548 Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli
MG et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose
and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61–64.
549 Lee YH, Lee HS, Choi SJ, Dai Ji J, Song GG. Efficacy and safety of tacrolimus therapy
for lupus nephritis: a systematic review of clinical trials. Lupus 2011; 20: 636–640.
550 Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J et al. Mycophenolate
mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005; 100:
c92–c100.
551 Ginzler E, Dooley M, Aranow C, Kim M, Buyon J, Merrill JT et al. Mycophenolate
mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:
2219–2228.
552 Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A.
Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for
induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine
(Baltimore) 2010; 89: 227–235.
553 Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R et al. Randomized controlled
trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the
induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504–510.
554 Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate
mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J
Rheumatol 2011; 38: 69–78.
476 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS